miR-26a对骨肉瘤发生转移及治疗作用的研究进展  

Research progress of miR-26a on metastasis and treatment of osteosarcoma

作　　者：李广渝 王旭东 李明[1] LI Guang-yu;WANG Xu-dong;LI Ming(Department of Orthopaedics,The Second Hospital of Hebei Medical University,Shijiazhuang,Hebei,050000,China)

机构地区：[1]河北医科大学第二医院骨科,石家庄050000

出　　处：《中国骨与关节杂志》2024年第5期396-400,共5页Chinese Journal of Bone and Joint

基　　金：河北省自然科学基金项目(H2021206321)。

摘　　要：骨肉瘤是最常见的骨恶性肿瘤,儿童和青少年发病率高[1],好发于四肢长骨的干骺端,很少出现在中轴骨骼和其它部位[2]。局限性骨肉瘤患者5年生存率达到60%~70%,但发生骨转移的患者5年生存率大约只有20%[3]。骨肉瘤的常规治疗包括手术、新辅助治疗和放化疗[4],目前临床最常用手术联合辅助化疗[5]。由于骨肉瘤患者对化疗药物的耐药性、复发和远处转移等影响使得骨肉瘤患者的预后仍然很差[6]。因此,探索骨肉瘤发生和发展机制,对骨肉瘤治疗和改善患者预后具有重大意义。Osteosarcoma represents the most common form of bone malignant tumor with strong aggressiveness,easy metastasis,and chemotherapy resistance.The pathogenesis of osteosarcoma is yet to be fully elucidated.MicroRNAs are classified as noncoding small RNA with a length of 20-22 nucleotides,which are abnormally expressed in a variety of malignant tumors.miR-26a is an important member of the MicroRNA family,and its expression has been found to be associated with the occurrence,development,invasion,metastasis and drug resistance of osteosarcoma.Mechanism of miR-26a in osteosarcoma has important clinical significance for the diagnosis,treatment and prognosis of osteosarcoma.This article reviews the effects of miR-26a on the occurrence,development,invasion,metastasis and drug resistance of osteosarcoma,which provides a reference for the diagnosis and prediction of osteosarcoma.

关 键 词：骨肉瘤 微RNA 抗药性 肿瘤 miR-26a 综述 

分 类 号：R73[医药卫生—肿瘤]